TempraMed closes $1.18M financing with debentures and units
TORONTO - TempraMed Technologies Ltd. successfully raised $1,177,940 through a private placement, as announced in a press release. The financing included $600,000 in unsecured convertible debentures with a 10% annual interest rate, maturing on September 30, 2027. The debentures can be converted into common shares at $0.50 per share before maturity.
Additionally, 1,155,880 units were issued, each representing one common share and one warrant exercisable at C$1.00 per share until March 30, 2028. The company plans to use the funds for inventory expansion, product development, scaling sales and marketing globally, and bolstering working capital. TempraMed's proceeds were shared with qualified finders, with $40,456 allocated to their finder's fees and 80,912 common shares issued to them.
All securities are subject to a four-month-and-one-day restricted period after the closing date. This financing follows previous announcements made in September 2026. TempraMed specializes in temperature-controlled medication storage solutions, with products such as the VIVI Cap, VIVI Cap Smart, VIVI Epi, and VIVI Med, operating in North America, Europe, and Asia.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
